Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions
Sep 2026· European Journal of Clinical Pharmacology· Vol 82· 0 citations· 31 references
Medicine
TL;DR
Alemtuzumab-based therapy was associated with high response rates in T-PLL—approximately 85% frontline—and approximately one-third of transplanted patients achieved long-term survival, which are descriptive benchmarks derived from low-certainty, single-arm evidence and require prospective confirmation.
Therapy-related myeloid neoplasms (t-MNs), including therapy-related acute myeloid leukemia and myelodysplastic syndrome, are recognized late complications of cytotoxic therapies. With the expanding use of autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cell (CAR-T) therapy, the risk, timi...
Adeena Musheer, M. S. Mannan, M. W. Khan et al.· Annals of Hematology· 0 citations
AHSCT may be associated with improved inflammatory disease control and disability recovery compared with alemtuzumab in highly active MS, and should be interpreted as hypothesis-generating, given the very low certainty of the evidence and the reliance on observational data.
Naima Kebir, Salem Waleed, Yousef El Sayed et al.· Multiple Sclerosis and Relat...· 0 citations
Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myeloma. Indirect comparisons in heavily pretreated patients have favored cell therapy, but whether that hierarchy holds in early relapse is unknown. We analyzed randomized phase 3 trials comparin...
Maximilian Merz, J. Souto, P. Voorhees et al.· Journal of Hematology & Onco...· 0 citations
BACKGROUND
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population-level outcomes remain...
M. Brink, Arie C. van der Spek, J. Doorduijn et al.· European Journal of Haematol...· 0 citations
The 5-year overall survival of a DLI-based strategy can induce durable remission in patients with low-burden morphologic AML relapse after TCD alloSCT, even without prior cytoreduction.
J. Bergsma, E. Argiro, K. Oosterink et al.· Transplantation and Cellular...· 1 citation
Allogeneic hematopoietic cell transplantations (allo-HCT) is a procedure with long history and well-documented efficacy in treating various malignant and non-malignant diseases of the hematopoietic system. While there is a potential for late complications even over 10 years following allo-HCT, the data on longer observ...
Kajetan Karaszewski, Jakub Góra, M. Paluszewska et al.· Stem Cell Reviews and Report...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
